Why is Smith & Nephew stock sliding today?
Smith & Nephew shares fell about 5.9% to 1,126.5p after the company reported first-half 2026 results and cut its full-year underlying revenue growth forecast to about 4%–6% from ~6%. Q2 underlying revenue growth was 1.6% versus ~3.7% expected, citing weaker U.S. knee implant demand and temporary U.S. hip headwinds.
How this was made
The 30-second read
Why it matters
A revenue growth forecast cut and a Q2 underlying growth miss are likely to trigger near-term estimate reductions, even though profit-growth guidance was reaffirmed with additional efficiency savings.
Market read
Traders are reacting to a same-day guidance cut and Q2 growth miss tied to U.S. knee implants, overriding broader market strength.
What to watch
Tariff impacts are described as broadly neutral, and Sports Medicine is said to be performing strongly, which may partially offset orthopaedics weakness if the mix improves.
Background
The article frames the selloff around Smith & Nephew’s first-half 2026 results and a downgrade in full-year underlying revenue growth, citing ongoing U.S. knee implant demand softness.
Ticker impact
Smith & Nephew shares fell about 5.9% after it cut full-year underlying revenue growth guidance to 4%–6% from ~6% and missed Q2 growth (1.6% vs ~3.7% expected).
Bearish bias for the next several sessions as investors reprice the orthopaedics demand outlook and the credibility of the reaffirmed profit-growth guidance.
The article attributes the selloff to specific, newly disclosed financial guidance and segment headwinds (U.S. knee implants), which typically drives immediate estimate revisions.
Market effects
Orthopaedics medtech peers may face read-across risk if U.S. knee implant demand softness appears persistent.
UK market support was limited, with FTSE 100 flat as AstraZeneca fell, so SNN’s move likely dominated local sentiment for its name.
Limited spillover beyond medtech investors focused on U.S. implant demand trends.
Counterpoint
Reaffirmed trading profit growth guidance and $50 million efficiency savings could cushion downside if investors focus on margin resilience rather than revenue growth.
Key entities
- public_companySmith & Nephew
Orthopaedics and sports medicine medical device company whose first-half results included a full-year underlying revenue growth forecast cut.
- executiveDeepak Nath
CEO who cited ongoing U.S. knee implant challenges and temporary headwinds in U.S. hip implants.
- analyst_firmKepler Cheuvreux
Issued a prior downgrade to Hold with a reduced price target, cited as limiting near-term re-rating catalysts.
